CDX-0158
CDX-0158 (NCT02642016; KTN0158) is a humanized anti-c-Kit/CD117 IgG1κ monoclonal antibody. CDX-0158 effectively blocks the SCF-KIT signaling pathway and inhibits mast cell activation, but due to the retention of wild-type IgG1 Fc, it can induce mast cell degranulation through FcyR cross-linking, resulting in obvious infusion reactions. CDX-0158 can be used in research related to advanced refractory gastrointestinal stromal tumors.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
CDX-0158 induces FcγR-dependent degranulation in IFNγ-pretreated primary human mast cells[2].
CDX-0158 elicits potent ADCC activity against M-07e cells in a reporter-based assay[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Synonyms
NCT02642016; KTN0158
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
[1]. Eggel A, et al. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways. Immunol Rev. 2024;328(1):387-411. [Content Brief]
[2]. Alvarado D, et al. Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 2022;77(8):2393-2403. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CDX-0158 Related Classifications
HY-P992509 Related Classifications
Powered by Bioz
Keywords
- CDX-0158
- NCT02642016
- KTN0158
- CDX0158
- CDX 0158
- NCT 02642016
- NCT-02642016
- KTN0158
- KTN 0158
- KTN-0158
- c-Kit
- antibody-dependent cell-mediated cytotoxicity
- interferon gamma
- IFNγ-pretreated primary human mast cells
- M-07e cells
- healthy dogs
- KIT-expressing target cells
- KIT
- gastrointestinal stromal tumor patients
- apoptosis
- primary mast cells
- Inhibitor
- inhibitor
- inhibit